MediWound signs UAE burns treatment distribution deal
Under the terms of the agreement, Ghassan Aboud Group will have exclusive rights to market and distribute NexoBrid in the UAE.
Israeli burn and wound management biopharmaceutical company MediWound Ltd. (Nasdaq: MDWD) today announced it has signed a distribution agreement with UAE-based international conglomerate Ghassan Aboud Group (GAG) for NexoBrid for the treatment of severe burns. Under the terms of the agreement, GAG will have exclusive rights to market and distribute NexoBrid in the UAE. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.